673478-49-4
Chemical Structure
Elpamotide
- CAS No.: 673478-49-4
- Formula:C47H76N16O13
- Molecular Weight:1073.21
IUPAC Name: L-arginyl-L-phenylalanyl-L-valyl-L-prolyl-L-aspartylglycyl-L-asparaginyl-L-arginyl-L-isoleucine
InChIKey: ZAJHBCDPAUKEPU-GIKXZWSFSA-N
SMILES: N=C(N)NCCC[C@H](N)C(N[C@@H](CC1=CC=CC=C1)C(N[C@@H](C(C)C)C(N2[C@@H](CCC2)C(N[C@@H](CC(O)=O)C(NCC(N[C@@H](CC(N)=O)C(N[C@@H](CCCNC(N)=N)C(N[C@H](C(O)=O)[C@@H](C)CC)=O)=O)=O)=O)=O)=O)=O)=O
Biological Activity: Elpamotide is an epitope peptide derived from VEGFR2. Elpamotide induces cytotoxic T lymphocytes (CTLs) to kill VEGFR2-expressing endothelial cells. Elpamotide has potential immunostimulatory and antineoplastic activities. Elpamotide can be used in the research of cancer, such as pancreatic cancer[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Elpamotide | Elpamotide is an epitope peptide derived from VEGFR2. Elpamotide induces cytotoxic T lymphocytes (CTLs) to kill VEGFR2-expressing endothelial cells. Elpamotide has potential immunostimulatory and antineoplastic activities. Elpamotide can be used in the research of cancer, such as pancreatic cancer. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Yamaue H, et al. Randomized phase II/III clinical trial of elpamotide for patients with advanced pancreatic cancer: PEGASUS-PC Study. Cancer Sci. 2015 Jul;106(7):883-90. [Content Brief]
- [2]. Wada S, et al. Rationale for antiangiogenic cancer therapy with vaccination using epitope peptides derived from human vascular endothelial growth factor receptor 2. Cancer Res. 2005 Jun 1;65(11):4939-46. [Content Brief]
Keywords
